New Asthma Inhaler Shows Big Promise in Late-Stage TrialsAstraZeneca's Breztri Aerosphere shows significant improvements in asthma treatment, outperforming dual therapies in clinical trials.
AstraZeneca Bets Big on Cell Therapy with $1B ISOBiotech AcquisitionAstraZeneca will acquire ISOBiotech for $1 billion, enhancing its cell therapy capabilities and reducing treatment times significantly.
AstraZeneca Bets on New Cancer Treatments By Acquiring Fusion Pharmaceuticals for $2 Billion [AlphaEconomy=(Chicago) Jisun Kim Correspondent] AstraZeneca is acquiring Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company. AstraZeneca said on Nov. 18 (local time) that it is acquiring Fusion Pharmaceuticals for about $20 billion in cash as it bets on next-generation cancer treatments...
Must-Reads
1
Arrest warrants issued for 48 suspects brought from Cambodia
LATEST
2
S. Korea's exports down 7.8% in first 20 days of Oct.
LATEST
3
S. Korean man found dead in Cambodia: foreign ministry
LATEST
4
Remains of late S. Korean student tortured to death in Cambodia arrive home
LATEST
5
Trump expects 'fantastic' trade deal with China, notes 'fair' deals with S. Korea, Japan, EU
New Asthma Inhaler Shows Big Promise in Late-Stage Trials AstraZeneca's Breztri Aerosphere shows significant improvements in asthma treatment, outperforming dual therapies in clinical trials.
AstraZeneca Bets Big on Cell Therapy with $1B ISOBiotech Acquisition AstraZeneca will acquire ISOBiotech for $1 billion, enhancing its cell therapy capabilities and reducing treatment times significantly.
AstraZeneca Bets on New Cancer Treatments By Acquiring Fusion Pharmaceuticals for $2 Billion [AlphaEconomy=(Chicago) Jisun Kim Correspondent] AstraZeneca is acquiring Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company. AstraZeneca said on Nov. 18 (local time) that it is acquiring Fusion Pharmaceuticals for about $20 billion in cash as it bets on next-generation cancer treatments...
Hot Topics